| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
PKCι (protein kinase C iota), an atypical PKC isoform involved in cell polarity, proliferation, and survival. Inhibition blocks PKCι-mediated signaling, which is important in oncogenic transformation and cancer cell growth. The compound shows selectivity over PKC-α and PKC-ε.
|
|---|---|
| ln Vitro |
PKCiota-IN-2 inhibits PKCι with an IC50 of 2.8 nM. It also inhibits PKC-α and PKC-ε with IC50 values of 71 nM and 350 nM, respectively, indicating approximately 25-fold selectivity for PKCι over PKC-α and 125-fold over PKC-ε.
|
| ln Vivo |
Publicly available in vivo efficacy data for this specific compound are limited. PKCι inhibitors as a class show antitumor activity in xenograft models, but compound-specific pharmacokinetic and efficacy data for PKCiota-IN-2 require confirmation from primary pharmacology studies.
|
| Enzyme Assay |
PKCι kinase inhibition is measured using recombinant PKCι and a peptide substrate in the presence of ATP and lipid cofactors. Serial dilutions of compound are pre-incubated with the kinase, and phosphorylation is detected by radiometric or fluorescence-based methods.
|
| Cell Assay |
Cancer cells are treated with serial dilutions of compound for 72 hours, and cell viability is measured by ATP assays. PKCι pathway inhibition is assessed by immunoblotting for phospho-substrates or downstream signaling markers.
|
| Animal Protocol |
Xenograft studies use immunocompromised mice bearing PKCι-dependent tumors. Compound is administered by intraperitoneal or oral routes, and tumor volume is measured. Tumor tissue is analyzed for PKCι pathway inhibition and apoptosis.
|
| References |
| Molecular Formula |
C24H21N5O
|
|---|---|
| Molecular Weight |
395.46
|
| Exact Mass |
395.174
|
| CAS # |
2230055-52-2
|
| Related CAS # |
PKCiota-IN-2 formic
|
| PubChem CID |
138393053
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.1
|
| tPSA |
67.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
604
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C2CNCCC2=C1)C3=C4C=C(C=CN4N=C3)C5=C6C=CNC6=NC=C5
|
| InChi Key |
PHOVPHVCAJYUNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H21N5O/c1-30-23-12-15-2-6-25-13-17(15)10-20(23)21-14-28-29-9-5-16(11-22(21)29)18-3-7-26-24-19(18)4-8-27-24/h3-5,7-12,14,25H,2,6,13H2,1H3,(H,26,27)
|
| Chemical Name |
6-methoxy-7-[5-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-1,2,3,4-tetrahydroisoquinoline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5287 mL | 12.6435 mL | 25.2870 mL | |
| 5 mM | 0.5057 mL | 2.5287 mL | 5.0574 mL | |
| 10 mM | 0.2529 mL | 1.2644 mL | 2.5287 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.